参考文献/References:
[1] Anand A, Singh KR, Kushwaha JK, et al. Papillary thyroid cancer and hashimoto’s thyroiditis:an association less understood[J].Indian J Surg Oncol, 2014, 5(3):199-204. DOI:10.1007/s13193-014-0325-4.
[2] Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland[J]. AMA Arch Surg, 1955, 70(2):291-297.
[3] Zhang Y, Ma XP, Deng FS, et al. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer[J]. World J Surg Oncol, 2014, 12:277. DOI:10.1186/1477-7819-12-277.
[4] Okayasu I, Fujiwara M, Hara Y, et al. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans[J]. Cancer, 1995, 76(11):2312-2318. DOI:10.1002/1097-0142(19951201)76:11<2312:AID-CNCR2820761120>3.0.CO; 2-H.
[5] Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited[J].World J Surg, 2001, 25(5):632-637. DOI:10.1007/s002680020165.
[6] Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2009, 71(4):581-586. DOI:10.1111/j.1365-2265.2009.03537.x.
[7] Caturegli P, De Remigis A, Chuang K, et al. Hashimoto’s thyroiditis:celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records[J]. Thyroid, 2013, 23(2):142-150. DOI:10.1089/thy.2012.0554.
[8] Konturek A, Barczyński M, Nowak W, et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis[J]. Langenbecks Arch Surg, 2014, 399(2):229-236. DOI:10.1007/s00423-013-1158-2.
[9] Lai X, Xia Y, Zhang B, et al. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk[J]. Oncotarget, 2017, 8(37):62414-62424. DOI:10.18632/oncotarget.18620.
[10] Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules[J]. Thyroid, 2010, 20(8):885-891. DOI:10.1089/thy.2009.0384.
[11] Knobel M, Medeiros-Neto G. Relevance of Iodine intake as a reputed predisposing factor for thyroid cancer[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):701-712. DOI:10.1590/S0004-273020070000500007.
[12] Mcleod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis:a systematic review and dose-response meta-analysis[J]. J Clin Endocrinol Metab, 2012, 97(8):2682-2692. DOI:10.1210/jc.2012-1083.
[13] Sadow PM, Heinrich MC, Corless CL, et al. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas[J]. Endocr Pathol, 2010, 21(2):73-79. DOI:10.1007/s12022-009-9101-3.
[14] Zhu F, Shen YB, Li FQ, et al. The effects of hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma a retrospective Chinese cohort study[J/OL]. Medicine (Baltimore), 2016, 95(6):e2674[2017-06-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617515/. DOI:10.1097/MD.0000000000002674.
[15] Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis:a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3):343-349. DOI:10.1530/EJE-12-0903.
[16] Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto’s thyroiditis and thyroid cancer in 64628 Patients[J/OL]. Front Oncol, 2017, 7:53[2017-06-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385456/. DOI:10.3389/fonc.2017.00053.
[17] Huang BY, Hseuh C, Chao TC, et al. Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence[J]. Endocr Pathol, 2011, 22(3):144-149. DOI:10.1007/s12022-011-9164-9.
[18] Ma B, Wang Y, Yang SW, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma:A systematic review and meta-analysis[J]. Int J Surg, 2016, 28:153-161. DOI:10.1016/j.ijsu.2016.02.093.
[19] Singh B, Shaha AR, Trivedi H, et al. Coexistent hashimoto’s thyroiditis with papillary thyroid carcinoma:impact on presentation, management, and outcome[J]. Surgery, 1999, 126(6):1070-1076; discussion 1076-1077.
[20] Jeong JS, Kim HK, Lee CR, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma:clinical manifestation and prognostic outcome[J]. J Korean Med Sci, 2012, 27(8):883-889. DOI:10.3346/jkms.2012.27.8.883.
[21] Dobrinja C, Makovac P, Pastoricchio M, et al. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome[J/OL]. Int J Surg, 2016, 28(S1):S70-74[2017-06-26]. https://linkinghub.elsevier.com/retrieve/pii/S1743-9191(15)01449-1. DOI:10.1016/j.ijsu.2015.12.059.
[22] Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer:initiators, amplifiers or an Achilles’ heel?[J]. Nat Rev Cancer, 2014, 14(11):709-721. DOI:10.1038/nrc3803.
[23] Loh KC, Greenspan FS, Dong F, et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84(2):458-463. DOI:10.1210/jcem.84.2.5443.
[24] Bagnasco M, Venuti D, Paolieri F, et al. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid:prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity[J]. J Clin Endocrinol Metab, 1989, 69(4):832-836. DOI:10.1210/jcem-69-4-832.
[25] Lucas SD, Karlssonparra A, Nilsson B, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma[J]. Hum Pathol, 1996, 27(12):1329-1335. DOI:10.1016/S0046-8177(96)90346-9.
[26] Cunha LL, Ferreira RC, Marcello MA, et al. Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer[J/OL]. J Thyroid Res, 2011:387062[2017-06-26]. https://www.hindawi.com/journals/jtr/2011/387062/. DOI:10.4061/2011/387062.
[27] Li W, Ming H, Sun D, et al. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma[J].Pathol Res Pract, 2016, 213(3):183-188. DOI:10.1016/j.prp.2016.12.022.
[28] Giordano C, Stassi G, Demaria R, et al. Potential involvement of fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis[J]. Science, 1997, 275(532):960-963. DOI:10.1126/science. 275.5302. 960.
[29] Tano T, Okamoto M, Kan S, et al. Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma[J]. Neoplasia, 2013,15(3):305-314. DOI:10.1593/neo.121528.
[30] Pyzik A, Grywalska E, Matyjaszek-Matuszek B, et al. Immune disorders in hashimoto’s thyroiditis:what do we know so far?[J/OL]. J Immunol Res, 2015,(2015):979167[2017-06-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426893/. DOI:10.1155/2015/979167.
[31] Zhang Q, Liu BJ, Ren WW, et al. Association between BRAFV600E mutation and ultrasound features in papillary thyroid carcinoma patients with and without Hashimoto’s thyroiditis[J]. Sci Rep, 2017, 7(1):4899. DOI:10.1038/s41598-017-05153-y.
[32] Pelizzo MR, Dobrinja C, Ide EC, et al. The role of BRAFV600E mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma[J]. Biomed Pharmacother, 2014, 68(4):413-417. DOI:10.1016/j.biopha.2014.03.008.
[33] Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment:a systematic review and meta-analysis[J]. Medicine (Baltimore), 2012, 91(5):274-286. DOI:10.1097/MD.0b013e31826a9c71.
[34] Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAFV600E in papillary thyroid carcinoma[J]. Endocr Relat Cancer, 2016, 23(1):27-34. DOI:10.1530/ERC-15-0408.
[35] Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J].Thyroid, 2009,19(2):137-141.DOI:10.1089/thy.2008.0144.
[36] Marotta V, Guerra A, Zatelli MC, et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto’s thyroiditis lymphocytic infiltration is present[J]. Clin Endocrinol (Oxf), 2013, 79(5):733-738.DOI:10.1111/cen.12194.